A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer (Q36623473)

15 August 2017

A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer (English)

1 reference

15 August 2017

1 reference

James ND

1

1 reference

15 August 2017

Atherton PJ

2

1 reference

15 August 2017

Jones J

3

1 reference

15 August 2017

Howie AJ

4

1 reference

15 August 2017

Tchekmedyian S

5

1 reference

15 August 2017

Curnow RT

6

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 July 2001

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

85

1 reference

15 August 2017

2

1 reference

15 August 2017

152-156

1 reference

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

15 August 2017

start time

1 July 2001

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1054/bjoc.2001.1878

0 references

cites work

A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364053

From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364053

Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364053

HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364053

The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364053

30 September 2017

Bispecific antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364053

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364053

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364053

Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364053

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364053

Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364053

Localized hypothermia: impact on oxygenation, microregional perfusion, metabolic and bioenergetic status of subcutaneous rat tumours

20 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1054%2FBJOC.2001.1878

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1054%2FBJOC.2001.1878

Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas

21 January 2018

1 reference

12 December 2020

Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials

1 reference

12 December 2020

The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate

1 reference

12 December 2020

Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer

1 reference

12 December 2020

Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer

1 reference

12 December 2020

Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis

1 reference

12 December 2020

Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (Tla) prostatic adenocarcinoma

1 reference

12 December 2020

Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function

1 reference

12 December 2020

Evaluation of the antibody-dependent cytotoxic capabilities of individual human monocytes. Role of Fc gamma RI and Fc gamma RII and the effects of cytokines at the single cell level

1 reference

12 December 2020

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

1 reference

12 December 2020

Identifiers

DOI

10.1054/BJOC.2001.1878

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

PubMed publication ID

11461069

1 reference